Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 370Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 Table of Contents      
LETTER TO EDITOR
Year : 2014  |  Volume : 5  |  Issue : 2  |  Page : 91

Development of pharmacoeconomics guidelines for India


1 ISPOR India-Andhra Pradesh Chapter, Anantapur, Andhra Pradesh, India
2 Department of Infectious Diseases, Rural Development Trust Hospital, Bathalapalli, Anantapur, Andhra Pradesh, India

Date of Web Publication1-Mar-2014

Correspondence Address:
Dixon Thomas
Department of Pharmacy Practice, Raghavendra Institute of Pharmaceutical Education and Research, Anantapur, Andhra Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2229-3485.128030

Rights and Permissions

How to cite this article:
Thomas D, Zachariah S, Reddy Y P, Alvarez-Uria G. Development of pharmacoeconomics guidelines for India. Perspect Clin Res 2014;5:91

How to cite this URL:
Thomas D, Zachariah S, Reddy Y P, Alvarez-Uria G. Development of pharmacoeconomics guidelines for India. Perspect Clin Res [serial online] 2014 [cited 2020 Jan 24];5:91. Available from: http://www.picronline.org/text.asp?2014/5/2/91/128030

Sir,

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is preparing pharmacoeconomics guidelines for India. The health-care delivery in each country is influenced by local and global politics. [1]

India has a strong price control mechanism through the National Pharmaceutical Pricing Authority. A mix of social, voluntary, private and community-based health insurance plans are available in India. Although the government pays only for approximately 20% of drugs used in India, [1] private out-of-pocket expenditure in India on health-care is one of the highest in the world. Increased public funding combined with flexibility of financial transfers from center to state can greatly improve the performance of state-operated public systems. Just by increasing public health-care funding would not help the quality of health-care delivery unless there are strictly implemented robust pharmacoeconomics guidelines in place. [2] In New Delhi, Mumbai, and Trivandrum, state authorities have invited the National Institute for Health and Clinical Excellence to help in the development of clinical guidelines. [3]

Preparing pharmacoeconomics guidelines will be an important step in order to establish health technology assessment (HTA) in India. Areas in which HTA could be applied in the Indian context include, drug pricing, development of clinical practice guidelines and prioritizing interventions that represent the greatest value with in a limited budget. [4]

India is planning to be part of universal health coverage scheme by 2022. It is a big capacity building challenge for central and state governments to provide high quality health-care without financial hardship on the health-care seekers. It is important to focus on preventive and public health strategies aimed at reducing the most important health problems in India. Recent advancements in high quality primary health-care including maternal and child health services by the State Tamil Nadu is encouraging. [5]

Challenges in developing and implementing pharmaco-economics guideline could be managed by involvement of all stakeholders. Some suggestions are as follows:

  • Constituting pharmacoeconomics advisory groups for central and state drug regulators
  • Implement HTA using pharmacoeconomics guidelines.
  • Concentrate on both direct and indirect services to decrease the burden of ailments such as improving nutrition, decrease poverty, develop infrastructure for health-care and living healthy and prevent transmission of diseases by treating patients and immunizing public
  • Improve access to life-saving medicines and afford ability of essential medicines
  • Implementing public, public-private partnership medical insurance systems linked with Aadhar card
  • Collect health-care tax and increase spending on health budgets
  • Creating awareness in public and professionals for better resource utilization
  • Consider health-care as a basic necessity, individual right and responsibility
  • Include pharmacoeconomics principles in medical, pharmacy, nursing, public health and other health-care professional education.


 
   References Top

1.Thatte U, Hussain S, de Rosas-Valera M, Malik MA. Evidence-based decision on medical technologies in Asia Pacific: Experiences from India, Malaysia, Philippines, and Pakistan. Value Health 2009;12 Suppl 3:S18-25.  Back to cited text no. 1
    
2.Kumar AK, Chen LC, Choudhury M, Ganju S, Mahajan V, Sinha A, et al. Financing health care for all: Challenges and opportunities. Lancet 2011;377:668-79.  Back to cited text no. 2
    
3.NICE. Summary of NICE international visit to Kerala, October 2009. Available from: http://www.nice.org.uk/. [Last cited on 2013 Jul 27].  Back to cited text no. 3
    
4.Hass B, Pooley J, Feuring M, Suvarna V, Harrington AE. Health technology assessment and its role in the future development of the Indian healthcare sector. Perspect Clin Res 2012;3:66-72.  Back to cited text no. 4
[PUBMED]  Medknow Journal  
5.Singh Z. Universal health coverage for India by 2022: A utopia or reality? Indian J Community Med 2013;38:70-3.  Back to cited text no. 5
[PUBMED]  Medknow Journal  




 

Top
  
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed1325    
    Printed23    
    Emailed1    
    PDF Downloaded329    
    Comments [Add]    

Recommend this journal